智通财经网·2026-03-04 08:37Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval for the registration of Saxagliptin Metformin Extended-Release Tablets, which will enhance its diabetes treatment product line and improve its overall competitiveness in the market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Saxagliptin Metformin Extended-Release Tablets (I) and (III) from the National Medical Products Administration [1] - This product is indicated for adult patients with type 2 diabetes to improve blood glucose control when used in conjunction with diet and exercise [1] Group 2: Market Potential - The product is not intended for patients with type 1 diabetes or diabetic ketoacidosis [1] - Saxagliptin Metformin Extended-Release Tablets are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) [1] - The estimated sales revenue for Saxagliptin Metformin Extended-Release Tablets in Chinese public medical institutions is approximately RMB 419 million in 2024 [1] Group 3: Strategic Implications - The approval of Saxagliptin Metformin Extended-Release Tablets will enrich the company's diabetes medication portfolio [1] - This development is expected to enhance the company's comprehensive competitiveness in the pharmaceutical industry [1]